C4 Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

C4 TherapeuticsDer Gewinn des Unternehmens wird voraussichtlich um 5.9% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 31.4% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich wachsen um 4.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -555.8% betragen.

Wichtige Informationen

-5.9%

Wachstumsrate der Gewinne

4.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	31.4%
Zukünftige Eigenkapitalrendite	-555.8%
Analystenabdeckung	Good
Zuletzt aktualisiert	21 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Feb 24

Recent updates

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk

Nov 15

C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout

Nov 06

We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

Oct 02

Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher

Aug 09

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up

Aug 03

Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

May 12

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

Mar 01

Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

Feb 29

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Feb 24

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

Nov 03

Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week

May 14

C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors

Sep 29

C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M

Aug 04

Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00

May 10

C4 Therapeutics: Poor Data Destroyed Preclinical Promise

May 04

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:CCCC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	21	-170	-150	-145	6
12/31/2025	44	-149	-137	-93	7
12/31/2024	36	-108	-105	-77	8
9/30/2024	34	-105	-72	-71	N/A
6/30/2024	29	-108	-79	-78	N/A
3/31/2024	20	-126	-93	-92	N/A
12/31/2023	21	-132	-109	-107	N/A
9/30/2023	20	-135	-115	-112	N/A
6/30/2023	16	-140	-115	-109	N/A
3/31/2023	27	-131	-118	-112	N/A
12/31/2022	31	-128	-111	-106	N/A
9/30/2022	48	-107	-107	-102	N/A
6/30/2022	50	-99	-94	-93	N/A
3/31/2022	46	-95	-90	-89	N/A
12/31/2021	46	-84	-88	-87	N/A
9/30/2021	34	-80	-84	-83	N/A
6/30/2021	34	-82	-81	-79	N/A
3/31/2021	34	-73	-76	-76	N/A
12/31/2020	33	-66	-68	-67	N/A
9/30/2020	33	-67	-56	-56	N/A
6/30/2020	30	-52	-50	-49	N/A
3/31/2020	24	-47	1	2	N/A
12/31/2019	21	-43	54	56	N/A
12/31/2018	19	-24	-20	-17	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CCCC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CCCC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CCCC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CCCCDie Einnahmen des Unternehmens (31.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: CCCCDie Einnahmen des Unternehmens (31.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CCCC wird voraussichtlich in 3 Jahren unrentabel sein.

C4 Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 24%, EPS downgraded

Consensus EPS estimates upgraded to US$1.59 loss, revenue downgraded

Price target decreased by 30% to US$11.88

Consensus revenue estimates increase by 12%

Price target increased by 8.0% to US$16.00

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Recent updates

C4 Therapeutics, Inc. Appoints Steve Hoerter as Board of Directors

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk

Consensus revenue estimates increase by 24%, EPS downgraded

C4 Therapeutics, Inc. Announces First Patient Dosed in CFT8919 Clinical Trial

C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma At the American Society of Hematology Annual Meeting

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

C4 Therapeutics, Inc. Announces Executive Changes

We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate

C4 Therapeutics, Inc. Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept from Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at European Society for Medical Oncology Congress 2024

C4 Therapeutics, Inc. Announces Board Changes

Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher

New minor risk - Profitability

C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

C4 Therapeutics, Inc. Announces Board and Committee Changes

Consensus EPS estimates upgraded to US$1.59 loss, revenue downgraded

Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

Price target decreased by 30% to US$11.88

New major risk - Revenue and earnings growth

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

C4 Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

C4 Therapeutics, Inc. Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

Consensus revenue estimates increase by 12%

Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

Price target increased by 8.0% to US$16.00

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Full year 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Price target decreased by 13% to US$15.50

C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.

C4 Therapeutics, Inc. Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

New major risk - Share price stability

C4 Therapeutics, Inc. Appoints Owen Hughes to Its Board of Directors

Price target decreased by 13% to US$16.20

Price target decreased by 12% to US$16.40

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

Third quarter 2023 earnings released

New major risk - Revenue and earnings growth

Price target decreased by 31% to US$13.11

C4 Therapeutics, Inc. Announces Upcoming Data Presentations for CFT8634 and CFT7455

Price target increased by 7.4% to US$20.40

Consensus revenue estimates decrease by 27%, EPS upgraded

Price target decreased by 9.3% to US$17.23

C4 Therapeutics, Inc. Appoints Mary Christian as Senior Vice President, Regulatory

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Share price stability

C4 Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for CFT8919

C4 Therapeutics, Inc.(NasdaqGS:CCCC) dropped from Russell Small Cap Comp Value Index

C4 Therapeutics, Inc. Appoints Leonard (Len) Reyno as Chief Medical Officer, Effective July 10, 2023

C4 Therapeutics, Inc. announced that it expects to receive $25 million in funding from Betta Pharmaceuticals Co., Ltd.

Price target decreased by 8.1% to US$19.23

Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week

Consensus revenue estimates decrease by 16%, EPS upgraded

Price target decreased by 30% to US$14.83

Price target increased by 10% to US$23.73

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates decrease by 17%

Full year 2022 earnings: EPS and revenues miss analyst expectations

C4 Therapeutics, Inc. Announces Executive Changes

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC(Tm) Degrader, in BRAF V600 Mutant Solid Tumors

Price target decreased to US$23.46

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers

C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors

Consensus revenue estimates increase by 16%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations